Search

Objective: To study histopathological and clinicopathological findings in a case series of Extra Nodal Non Hodgkin Lymphomas (EN NHL). Materials and Methods: 17 cases of primary ENNHLs, collected during a period of November 2019 to November 2020 (one year), wherein the clinical data included age, gender, site, clinical presentation and radiological findings were collected. Haematoxylin and eosin staining was done along with Immunohistochemistry (IHC) using a panel of antibodies depending on the morphology. Result: 17 cases of primary ENNHLs taken. Majority of our patients were from higher age group, presenting in sixth decade, though the age range was wide between 5-92 years. Our study included 12 males and 5 females, with a male: female ratio of 2.4:1. We found retroperitoneal masses and GIT as the most common site for ENNHLs.Weight loss followed by fever was the most common clinical presentation in our study presentation. Ann Arbor Staging was done in 16/17 cases where 35% (6/17) belonged to stage I, 35% (6/17) cases belonged to stage II, 17.6 (3/17) belonged to stage III and 1.5% (1/17) belonged to stageIV. Eastern cooperative oncology group performance scale (ECOG) was also calculated and documented. Conclusion: This study highlights importance of diagnosing Extranodal NonHodgkin’s lymphomas as a separate entity since its clinical presentation, prognosis, staging and management differs from Nodal NonHodgkins lymphoma. Keywords: Immunohistochemistry, Extranodal, NonHodgkin lymphoma.

Gall bladder carcinoma (GBC) is a multi-factorial disease, involving multiple genetic alterations. The present pilot study aims to explore some of the molecular pathways, by studying immunohistochemical (IHC) expression of biomarkers (HER2/neu, KRAS, and VEGF) in GBC with their correlation with various clinicopathological parameters.To study the expression of prognostic biomarkers (HER2/neu, KRAS and VEGF-A) in GBC and their correlation with clinico-morphological parameters. Materials and.This prospective study was conducted over a period of 2 years. The study group included tissue of GBC (29) reported as malignant on histopathology and cholecystitis as a control group (29) for histopathological evaluation and IHC expression of above markers.HER2/neu was expressed in 27.5% cases, and KRAS in 51.6%; however, both showed no association with tumor type, stage and grade. No association was found in KRAS expression and dysplasia. Vascular Endothelial Growth Factor - A (VEGF-A) was expressed in 86.1% cases, of which strong positivity was seen in 48.27%; it showed significant association with tumor stage (P value-0.027, Fishers' exact test), hence possibly suggesting its role in tumor progression; though no association was found in VEGF expression with tumor type and grade. No significant association was seen with vascular and tumor invasion also.The results suggest that the VEGF-A expression may be used as a potential prognostic biomarker in GBC.

Aims & Objectives: To assess utility of haematological parameters and infection biomarkers in identifying COVID19 disease severity Patients/Materials & Methods: The test results for complete blood counts, Coagulation screen and inflammatory markers of 100 covid 19 positive patients were recorded and analysed based on their admission to Intensive care units,High Dependency Units or Ward Those parameters with significant differences were assessed by receiver operating curve and the best screening cut-off was selected Results: 100 adults were analysed, area under the curve for total leukocyte count (TLC), Absolute neutrophil count (ANC), Neutrophil- to-Lymphocyte ratio (NLR) was found>0 800, with p